OKYO Pharma Corporation Result of General Meeting and Corporate Update (2717H)
March 09 2018 - 6:01AM
UK Regulatory
TIDMOKYO
RNS Number : 2717H
OKYO Pharma Corporation
09 March 2018
9 March 2018
For immediate release
OKYO Pharma Corporation
Result of General Meeting
Corporate Update
OKYO Pharma Corporation (the "Company") (AIM: OKYO) announces
that the resolution put to Shareholders at the General Meeting held
earlier today was duly passed. The resolution was proposed as a
special resolution of Shareholders to:
(a) change the name of the Company to OKYO Pharma Limited with effect from Migration;
(b) approve the Migration to Guernsey; adopt, with effect from
Migration, the Company's new memorandum and articles of
incorporation compliant with Guernsey law, in place of the
Company's existing memorandum and Articles;
(c) disapply the pre-emption rights as set out in the New Articles; and
(d) approve Cancellation of admission of its Ordinary Shares from trading on AIM.
As previously announced, cancellation of admission of its
Ordinary Shares from trading on AIM will take effect at 7.00 a.m.
on 23 March 2018.
Broker
As announced on 2 March 2018, the Company is seeking to appoint
a new broker as soon as possible and a further announcement will be
made when this appointment is made.
Special Dividend
The Company has finalised the arrangements for completion of the
Special Dividend and the Board currently anticipates payments of
the Special Dividend later this month.
For further information contact:
OKYO Pharma Corporation Willy Simon +44 (0)20 7382 8300
Roland Cornish
Beaumont Cornish Limited (Nominated Adviser) Michael Cornish +44 (0)20 7628 3396
Further information is available on the Company's website:
www.okyopharma.com
This announcement is inside information for the purposes of
Article 7 of Regulation 596/2014. The person who arranged for the
release of this announcement on behalf of the Company was Willy
Simon, Director.
APPENDIX
DEFINITIONS
In this announcement, the following expressions have the
following meanings unless the context otherwise requires:
"AIM" the market of that name operated
by the London Stock Exchange
"Articles" articles of association or articles
of incorporation of the Company
in force from time to time including,
with effect from Migration, the
New Articles
"Cancellation" the proposed cancellation of admission
of the Ordinary Shares from trading
on AIM
"Company" or (i) as at the date of this document,
"OKYO" OKYO Pharma Corporation, and (ii)
subject to re-registration following
Cancellation and completion of the
Migration, OKYO Pharma Limited.
"Ferrum" Ferrum Resources Limited
"Ferrum Shares" the ordinary shares of no par value
in the capital of Ferrum
"General Meeting" the general meeting of the Company
held at 10.00 a.m. on 9 March 2018
"Migration" the continuation of the Company
out of the British Virgin Islands
and migration of the Company into
Guernsey
"New Articles" the proposed new articles of incorporation
compliant with Guernsey law, to
be adopted upon Migration in place
of the Company's existing articles
of association
"Ordinary Shares" ordinary shares of no par value
in the capital of the Company
"Shareholders" holders of Ordinary Shares
"Special Dividend" the distribution of Ferrum Shares
to Shareholders
ENDS
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFKCDPKBKDFNK
(END) Dow Jones Newswires
March 09, 2018 06:01 ET (11:01 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From May 2023 to May 2024